Antibody targeting of mutant calreticulin in myeloproliferative neoplasms
Abstract
Mutations in calreticulin are one of the key disease‐initiating mutations in myeloproliferative neoplasms (MPN). In MPN, mutant calreticulin translates with a novel C‐terminus that leads to aberrant binding to the extracellular domain of the thrombopoietin receptor, MPL. This cell surface neoantigen has become an attractive target for immunological intervention. Here, we summarize recent advances in the development of mutant calreticulin targeting antibodies as a novel therapeutic approach in MPN.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 07, 2023
- Source ID
- 10.1111/jcmm.17896
Entities
People
- Ann Mullally
- Frederike Kramer
Organizations
- Broad Institute
- Congressionally Directed Medical Research Programs
- Dana–Farber Cancer Institute
- Harvard Medical School
- Leukemia & Lymphoma Society
- National Heart, Lung, and Blood Institute